Comparing Interpace Biosciences (OTCMKTS:IDXG) & Nemaura Medical (OTCMKTS:NMRD)

Volatility and Risk

Interpace Biosciences has a beta of 0.65, meaning that its share price is 35% less volatile than the S&P 500. Comparatively, Nemaura Medical has a beta of -0.07, meaning that its share price is 107% less volatile than the S&P 500.

Insider and Institutional Ownership

5.7% of Interpace Biosciences shares are held by institutional investors. Comparatively, 4.4% of Nemaura Medical shares are held by institutional investors. 5.5% of Interpace Biosciences shares are held by insiders. Comparatively, 40.4% of Nemaura Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Interpace Biosciences and Nemaura Medical”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Interpace Biosciences	$38.73 million	0.24	$24.58 million	($0.02)	-105.51
Nemaura Medical	N/A	N/A	N/A	($0.50)	0.00

Interpace Biosciences has higher revenue and earnings than Nemaura Medical. Interpace Biosciences is trading at a lower price-to-earnings ratio than Nemaura Medical, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Interpace Biosciences and Nemaura Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Interpace Biosciences	63.46%	493.02%	137.46%
Nemaura Medical	N/A	N/A	N/A

Summary

Interpace Biosciences beats Nemaura Medical on 7 of the 9 factors compared between the two stocks.

About Interpace Biosciences

Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.

About Nemaura Medical

Nemaura Medical Inc., a medical technology company, manufactures continuous glucose monitoring system in the United States. It offers sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.